Gastroenterology

Papers
(The H4-Index of Gastroenterology is 108. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
Evidence for Gastrointestinal Infection of SARS-CoV-22036
MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease1741
Gastrointestinal Manifestations of SARS-CoV-2 Infection and Virus Load in Fecal Samples From a Hong Kong Cohort: Systematic Review and Meta-analysis1103
COVID-19: Gastrointestinal Manifestations and Potential Fecal–Oral Transmission1022
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goal996
Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization976
Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study855
Global Burden of 5 Major Types of Gastrointestinal Cancer835
Nonalcoholic Fatty Liver Disease 2020: The State of the Disease676
Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry558
Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis551
Efficacy of Real-Time Computer-Aided Detection of Colorectal Neoplasia in a Randomized Trial347
The Microbiota-Gut-Brain Axis: From Motility to Mood343
AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis333
Pancreatic Injury Patterns in Patients With Coronavirus Disease 19 Pneumonia317
Mechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis316
Differences in Gut Microbiota in Patients With vs Without Inflammatory Bowel Diseases: A Systematic Review314
Bariatric Surgery Provides Long-term Resolution of Nonalcoholic Steatohepatitis and Regression of Fibrosis300
AGA Institute Rapid Review of the Gastrointestinal and Liver Manifestations of COVID-19, Meta-Analysis of International Data, and Recommendations for the Consultative Management of Patients with COVID291
Inflammatory Bowel Diseases (IBD) and the Microbiome—Searching the Crime Scene for Clues266
Extraintestinal Manifestations of Inflammatory Bowel Disease: Current Concepts, Treatment, and Implications for Disease Management254
Mechanisms, Evaluation, and Management of Chronic Constipation251
Clinical Characteristics and Outcomes of Coronavirus Disease 2019 Among Patients With Preexisting Liver Disease in the United States: A Multicenter Research Network Study251
Prevalence of Rome IV Functional Bowel Disorders Among Adults in the United States, Canada, and the United Kingdom244
AGA Clinical Practice Update on Lifestyle Modification Using Diet and Exercise to Achieve Weight Loss in the Management of Nonalcoholic Fatty Liver Disease: Expert Review235
AGA Rapid Recommendations for Gastrointestinal Procedures During the COVID-19 Pandemic234
Prevalence and Characteristics of Gastrointestinal Symptoms in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection in the United States: A Multicenter Cohort Study233
Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2021230
Deep-Learning System Detects Neoplasia in Patients With Barrett’s Esophagus With Higher Accuracy Than Endoscopists in a Multistep Training and Validation Study With Benchmarking221
Alterations in Fecal Fungal Microbiome of Patients With COVID-19 During Time of Hospitalization until Discharge216
Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease214
Recommendations for Follow-Up After Colonoscopy and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer210
Gastrointestinal Symptoms and Coronavirus Disease 2019: A Case-Control Study From the United States206
The Global Landscape of Esophageal Squamous Cell Carcinoma and Esophageal Adenocarcinoma Incidence and Mortality in 2020 and Projections to 2040: New Estimates From GLOBOCAN 2020205
Clinical-Grade Detection of Microsatellite Instability in Colorectal Tumors by Deep Learning203
AGA Clinical Practice Guidelines on the Role of Probiotics in the Management of Gastrointestinal Disorders200
Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study197
Worldwide Burden of, Risk Factors for, and Trends in Pancreatic Cancer196
Contribution of the Intestinal Microbiome and Gut Barrier to Hepatic Disorders194
Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension193
AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review192
Pancreatic Cancer: Pathogenesis, Screening, Diagnosis, and Treatment186
Twenty-first Century Trends in the Global Epidemiology of Pediatric-Onset Inflammatory Bowel Disease: Systematic Review184
High-Fat Diet Promotes Colorectal Tumorigenesis Through Modulating Gut Microbiota and Metabolites183
Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis182
Colorectal Cancer in Inflammatory Bowel Disease: Mechanisms and Management180
Gastrointestinal Symptoms as a Major Presentation Component of a Novel Multisystem Inflammatory Syndrome in Children That Is Related to Coronavirus Disease 2019: A Single Center Experience of 44 Cases179
Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn’s Disease178
Endoscopic Removal of Colorectal Lesions—Recommendations by the US Multi-Society Task Force on Colorectal Cancer177
AGA Clinical Practice Update on Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: Expert Commentary177
AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters Clinical Guidelines for the Management of Eosinophilic Esophagitis176
Global Incidence of Acute Pancreatitis Is Increasing Over Time: A Systematic Review and Meta-Analysis174
MELD 3.0: The Model for End-Stage Liver Disease Updated for the Modern Era174
Effect of Gastrointestinal Symptoms in Patients With COVID-19172
High Prevalence of Concurrent Gastrointestinal Manifestations in Patients With Severe Acute Respiratory Syndrome Coronavirus 2: Early Experience From California168
The Healthy Microbiome—What Is the Definition of a Healthy Gut Microbiome?166
Metabolism and Metabolic Disorders and the Microbiome: The Intestinal Microbiota Associated With Obesity, Lipid Metabolism, and Metabolic Health—Pathophysiology and Therapeutic Strategies162
High-Fidelity Drug-Induced Liver Injury Screen Using Human Pluripotent Stem Cell–Derived Organoids161
Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis159
Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis159
Bile Acids Signal via TGR5 to Activate Intestinal Stem Cells and Epithelial Regeneration158
Cancer and the Microbiome—Influence of the Commensal Microbiota on Cancer, Immune Responses, and Immunotherapy155
Development and Validation of a Deep Neural Network for Accurate Evaluation of Endoscopic Images From Patients With Ulcerative Colitis155
Management of Patients With Crohn’s Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting155
Adipose Tissue-Liver Cross Talk in the Control of Whole-Body Metabolism: Implications in Nonalcoholic Fatty Liver Disease154
Epidemiology, Presentation, and Diagnosis of Celiac Disease152
Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naïve to Nucleos(t)ide Therapy152
Single-Cell Analyses of Colon and Blood Reveal Distinct Immune Cell Signatures of Ulcerative Colitis and Crohn’s Disease152
Development of the Microbiota and Associations With Birth Mode, Diet, and Atopic Disorders in a Longitudinal Analysis of Stool Samples, Collected From Infancy Through Early Childhood151
RNA N6-Methyladenosine Methyltransferase METTL3 Facilitates Colorectal Cancer by Activating the m6A-GLUT1-mTORC1 Axis and Is a Therapeutic Target151
Increased Intestinal Permeability Is Associated With Later Development of Crohn’s Disease149
AGA Clinical Practice Update on the Diagnosis and Management of Atrophic Gastritis: Expert Review147
Is SARS-CoV-2 Also an Enteric Pathogen With Potential Fecal–Oral Transmission? A COVID-19 Virological and Clinical Review144
Long-term Risk of Colorectal Cancer After Removal of Conventional Adenomas and Serrated Polyps143
Postacute COVID-19 is Characterized by Gut Viral Antigen Persistence in Inflammatory Bowel Diseases137
AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn’s Disease134
Therapeutic Landscape for NAFLD in 2020133
AGA Clinical Practice Update on Pancreas Cancer Screening in High-Risk Individuals: Expert Review133
Functional Dyspepsia and Gastroparesis in Tertiary Care are Interchangeable Syndromes With Common Clinical and Pathologic Features133
Human Pluripotent Stem Cell-Derived Organoids as Models of Liver Disease131
The Tight Junction Protein ZO-1 Is Dispensable for Barrier Function but Critical for Effective Mucosal Repair131
Pregnancy and Neonatal Outcomes After Fetal Exposure to Biologics and Thiopurines Among Women With Inflammatory Bowel Disease129
Enterotoxigenic Bacteroides fragilis Promotes Intestinal Inflammation and Malignancy by Inhibiting Exosome-Packaged miR-149-3p127
Lower Adenoma Miss Rate of Computer-Aided Detection-Assisted Colonoscopy vs Routine White-Light Colonoscopy in a Prospective Tandem Study126
Probiotics Reduce Mortality and Morbidity in Preterm, Low-Birth-Weight Infants: A Systematic Review and Network Meta-analysis of Randomized Trials125
Serum Biomarkers Identify Patients Who Will Develop Inflammatory Bowel Diseases Up to 5 Years Before Diagnosis123
Prolonged Impairment of Short-Chain Fatty Acid and L-Isoleucine Biosynthesis in Gut Microbiome in Patients With COVID-19123
Protective Role of Tacrolimus, Deleterious Role of Age and Comorbidities in Liver Transplant Recipients With Covid-19: Results From the ELITA/ELTR Multi-center European Study121
Deep Remission at 1 Year Prevents Progression of Early Crohn’s Disease118
Nonalcoholic Fatty Liver Disease: Modulating Gut Microbiota to Improve Severity?118
Synbiotics Alter Fecal Microbiomes, But Not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Nonalcoholic Fatty Liver Disease118
Therapeutic Interleukin-6 Trans-signaling Inhibition by Olamkicept (sgp130Fc) in Patients With Active Inflammatory Bowel Disease117
Prevalence of Gastroesophageal Reflux Disease and Proton Pump Inhibitor-Refractory Symptoms117
Differences in Fecal Microbiomes and Metabolomes of People With vs Without Irritable Bowel Syndrome and Bile Acid Malabsorption117
Uneventful Course in Patients With Inflammatory Bowel Disease During the Severe Acute Respiratory Syndrome Coronavirus 2 Outbreak in Northern Italy117
Succinate Produced by Intestinal Microbes Promotes Specification of Tuft Cells to Suppress Ileal Inflammation117
Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002–2020)116
An Update on the Epidemiology, Molecular Characterization, Diagnosis, and Screening Strategies for Early-Onset Colorectal Cancer114
Metabolic Inflammation—A Role for Hepatic Inflammatory Pathways as Drivers of Comorbidities in Nonalcoholic Fatty Liver Disease?114
AGA Clinical Practice Update on Diagnosis and Management of Immune Checkpoint Inhibitor Colitis and Hepatitis: Expert Review114
Risk Factors for Early-Onset Colorectal Cancer113
Multiomics Evaluation of Gastrointestinal and Other Clinical Characteristics of COVID-19112
Fecal Microbiota Transplantation Is Highly Effective in Real-World Practice: Initial Results From the FMT National Registry112
Gastrointestinal and Hepatic Manifestations of 2019 Novel Coronavirus Disease in a Large Cohort of Infected Patients From New York: Clinical Implications112
Streptococcus thermophilus Inhibits Colorectal Tumorigenesis Through Secreting β-Galactosidase110
Prognostic Factors for Advanced Colorectal Neoplasia in Inflammatory Bowel Disease: Systematic Review and Meta-analysis109
AGA Clinical Practice Update on the Management of Refractory Helicobacter pylori Infection: Expert Review108
HNF4 Regulates Fatty Acid Oxidation and Is Required for Renewal of Intestinal Stem Cells in Mice108
0.21213912963867